WorkThe story, in brief
OpenAI researcher Miles Wang in talks to launch AI drug discovery startup valued at $2B
$2B. That's the valuation for Miles Wang's AI drug discovery startup—and he's leaving OpenAI to build it.
The KeyNews take
Why it matters
Top AI researcher departure signals talent drain from labs to specialized AI applications. Validates investor thesis that AI's highest-ROI use cases lie in biotech, not consumer chat.
The key facts
5 to knowMiles Wang (OpenAI researcher) launching new startup
$2B valuation in funding discussions
Focus: AI drug discovery / life sciences applications
Signals investor appetite for AI-biotech vertical plays
Key talent migration from foundational model labs to domain-specific applications
Go to the source
TechCrunch AItechcrunch.com
Publisher excerpt: The funding discussions point to investor interest in applying AI to make breakthroughs in life sciences.